LEARNING OBJECTIVES

- To learn the biological basis and characterization of Colorectal Cancer (CRC)
- To understand the essentials in the assessment and the value of multidisciplinary management of patients with CRC
- To learn how to integrate and to sequence the available therapies in the management of a patient with advanced CRC integrating molecular and clinical information including direct exposure to real clinical scenarios
- To learn and discuss about future advances in diagnose and treatment of CRC

Friday, 3 December 2021

09:00-09:10  Welcome and course overview
Julien Taieb, FR and Elena Élez, ES

09:10-10:45  Session 1
Biological basis and characterization of CRC

20’  Genomic characterization of CRC
Andrea Sartore-Bianchi, IT

20’  The relevance of stroma in CRC
Filippo Pietrantonio, IT

20’  Role of microbiota in CRC
Elena Elez, ES
20’ Tumor Heterogeneity and Clonal evolution as a Hallmark in CRC
Clara Montagut, ES

15’ Discussion
Faculty

10:45-11:15 Coffee break

11:15-12:50 Session 2
Therapeutic approach in the early disease

20’ Optimizing perioperative treatment in rectal cancer
Jean-Baptiste Bachet, FR

20’ Is there a room for neoadjuvant treatment in colon cancer?
Jenny Seligmann, UK

20’ ctDNA in the early stage: Evidence and strategies
Clara Montagut, ES

20’ How to build an International collaborative Effort: The Circulate Paradigm
Julien Taieb, FR

15’ Discussion
Faculty

12:50-13:25 Professional Development Session:
How to build an efficient career path: Identifying the Key Stakeholders
Fortunato Ciardiello, IT

13:25-14:30 Lunch

14:30-15:45 Session 3
The continuum of care of mCRC: Managing specific situations

20’ State-of-the-art treatment of left sided RAS/BRAF native CRC. Must we consider and assess clonal evolution?
Jean-Baptiste Bachet, FR

20’ Maintenance Treatment in CRC: New Evidence
TBC

20’ New treatment options for refractory CRC
Erika Martinelli, IT

15’ Discussion
Faculty
15:45–16:25  Keynote lecture
Potentials of Single Cell Sequencing in cancer Research: Focus on CRC
Holger Heyn, ES

16:25-16:55  Coffee break

16:55-18:10  Session 4
Novel therapies

15’  The arena of HER2 in mCRC: When, how and new treatment options
Andrea Sartore Bianchi, IT

15’  Targeting MAP kinase pathway in CRC
Elena Elez, ES

15’  MSI-H/dMRR mCRC: Understanding The profile of response
Julien Taieb, FR

15’  Treatment strategies in MSS/pMMR mCRC
Filippo Pietrantonio, IT

15’  Discussion
Faculty

19:30  Networking dinner

Saturday, 4 December 2021

9:00-12:30  Workshop sessions
Three parallel workshops sessions with “20” delegates in each group (delegates will attend all 3 sessions on a rotation basis)

15’  Introduction of the topic on real examples presented by speakers
40’  Discussion
5’  Break

Workshop 1  Management of oligometastatic disease
60’  Jean-Baptiste Bachet, FR
    Erika Martinelli, IT

Workshop 2  Identifying advanced CRC patients for comprehensive molecular profiling: Who and When
60’  Clara Montagut, ES
    TBC
11:00-11:30  Coffee break

Workshop 3  Innovative trial Designs in advanced CRC
60'
Jenny Seligmann, UK
Filippo Pietrantonio, IT

12:30-13:00  Feedback on the workshops from each group

13:00-13:30  Synthesis and wrap-up
Julien Taieb, FR and Elena Élez, ES

13:30-14:30  Lunch